[go: up one dir, main page]

MX2017004761A - Uso de cannabinoides en el tratamiento de enfermedades degenerativas del musculo esqueletico. - Google Patents

Uso de cannabinoides en el tratamiento de enfermedades degenerativas del musculo esqueletico.

Info

Publication number
MX2017004761A
MX2017004761A MX2017004761A MX2017004761A MX2017004761A MX 2017004761 A MX2017004761 A MX 2017004761A MX 2017004761 A MX2017004761 A MX 2017004761A MX 2017004761 A MX2017004761 A MX 2017004761A MX 2017004761 A MX2017004761 A MX 2017004761A
Authority
MX
Mexico
Prior art keywords
cannabinoids
skeletal muscle
treatment
muscle diseases
degenerative
Prior art date
Application number
MX2017004761A
Other languages
English (en)
Other versions
MX364633B (es
Inventor
Stott Colin
Foster Keith
Di Marzo Vicenzo
Iannotti Fabio
Original Assignee
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Pharma Ltd filed Critical Gw Pharma Ltd
Publication of MX2017004761A publication Critical patent/MX2017004761A/es
Publication of MX364633B publication Critical patent/MX364633B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de cannabinoides en el tratamiento de una enfermedad degenerativa del músculo esquelético. En particular, la enfermedad degenerativa del músculo esquelético es distrofia muscular de Duchenne (DMD). Preferiblemente, los cannabinoides son uno o más de: cannabidiol (CBD); cannabidivarina (CBDV) y tetrahidrocannabivarina (THCV).
MX2017004761A 2014-10-14 2015-10-14 Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético. MX364633B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1418172.1A GB2531283A (en) 2014-10-14 2014-10-14 Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
PCT/GB2015/053044 WO2016059411A1 (en) 2014-10-14 2015-10-14 Use of cannabinoids in the treatment of degenerative skeletal muscle diseases

Publications (2)

Publication Number Publication Date
MX2017004761A true MX2017004761A (es) 2017-07-27
MX364633B MX364633B (es) 2019-05-03

Family

ID=52001394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004761A MX364633B (es) 2014-10-14 2015-10-14 Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético.

Country Status (11)

Country Link
US (1) US10226433B2 (es)
EP (1) EP3206681B1 (es)
JP (1) JP6655076B2 (es)
AU (1) AU2015332220B2 (es)
BR (1) BR112017007774A2 (es)
CA (1) CA2963211C (es)
ES (1) ES2732062T3 (es)
GB (1) GB2531283A (es)
IL (1) IL251530B (es)
MX (1) MX364633B (es)
WO (1) WO2016059411A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
CN111032088A (zh) 2017-06-20 2020-04-17 耶路撒冷希伯来大学伊森姆研究发展有限公司 大麻二酚酸酯类组合物及其用途
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
WO2019025474A1 (en) * 2017-08-02 2019-02-07 Centro Cardiologico Monzino S.p.A. MODULATION OF ENDOCANNABINOID SYSTEM AND USES IN THE CONTEXT OF INDUCED PLURIPOTENT STEM CELL-BASED APPLICATIONS AND THERAPY FOR CARDIOMYOPATHIES
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
JP7570108B2 (ja) * 2019-01-25 2024-10-21 ウニベルシタット、アウトノマ、デ、バルセロナ ミトコンドリア病の治療における使用のためのカンナビジオールおよび／またはその誘導体
EP3937925A1 (en) 2019-03-12 2022-01-19 EPM (IP), Inc. Cannabinoid acid ester compositions and uses thereof
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
CN113116869B (zh) * 2019-12-31 2022-08-23 汉义生物科技（北京）有限公司 一种预防和/或治疗抑郁的组合物
WO2021137224A1 (en) * 2020-01-01 2021-07-08 Epm Group, Inc. Cannabidiolic acid esters for treating muscular dystrophy
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2022122904A1 (en) 2020-12-09 2022-06-16 Chanelle Mccoy Cbd Limited A delayed-release capsule of cannabidiol
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
JPWO2024043242A1 (es) * 2022-08-23 2024-02-29

Also Published As

Publication number Publication date
EP3206681A1 (en) 2017-08-23
CA2963211C (en) 2023-09-05
AU2015332220A1 (en) 2017-04-20
JP6655076B2 (ja) 2020-02-26
WO2016059411A1 (en) 2016-04-21
ES2732062T3 (es) 2019-11-20
EP3206681B1 (en) 2019-04-10
MX364633B (es) 2019-05-03
AU2015332220B2 (en) 2020-10-01
BR112017007774A2 (en) 2018-01-16
IL251530A0 (en) 2017-05-29
US10226433B2 (en) 2019-03-12
GB201418172D0 (en) 2014-11-26
GB2531283A (en) 2016-04-20
IL251530B (en) 2019-10-31
US20170304217A1 (en) 2017-10-26
CA2963211A1 (en) 2016-04-21
JP2018502823A (ja) 2018-02-01
NZ730985A (en) 2024-01-26

Similar Documents

Publication Publication Date Title
MX2017004761A (es) Uso de cannabinoides en el tratamiento de enfermedades degenerativas del musculo esqueletico.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
MX2021010033A (es) Composiciones microencapsuladas de cannabinoides.
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
UY35210A (es) Inhibidores de autotaxina
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
MX2017016376A (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
MX378108B (es) Anticuerpos anti-met y composiciones.
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
AR102658A1 (es) Composición para el tratamiento de telas
MX2016015630A (es) Nuevos compuestos.
SV2016005301A (es) Nuevos compuestos macrocíclicos
CL2016002422A1 (es) Cromeno y 1, 1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasas.
DOP2017000073A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CL2018001104A1 (es) Composición para el cuidado de la piel y procedimiento asociado.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
ECSP16096831A (es) Derivados de naftiridinadiona
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.

Legal Events

Date Code Title Description
FG Grant or registration